- Subject has a clinically significant coagulopathy (i.e., activated partial thromboplastin time [aPTT] ≥ 1.5 times the upper limit opf normal (ULN) and/or prothrombin time adjusted for the international normalized ratio [PT-INR] ≥ 2.0).